| Pharmaceutical Information |
| Drug Name |
Acitretin |
| Drug ID |
BADD_D00036 |
| Description |
An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate. |
| Indications and Usage |
For the treatment of severe psoriasis in adults. |
| Marketing Status |
approved |
| ATC Code |
D05BB02 |
| DrugBank ID |
DB00459
|
| KEGG ID |
D02754
|
| MeSH ID |
D017255
|
| PubChem ID |
5284513
|
| TTD Drug ID |
D05QDC
|
| NDC Product Code |
17337-0003; 59981-011; 0093-1136; 0115-1752; 42291-087; 62147-0145; 0115-1751; 42794-081; 0378-7020; 71214-0698; 42291-088; 58159-058; 71052-692; 0115-1753; 17337-0004; 71214-0667; 0115-1750; 71214-0668; 71214-0669; 42291-086; 42794-080; 0093-1135; 0093-1138; 62147-0146; 76055-0001; 42794-083; 0378-7023 |
| UNII |
LCH760E9T7
|
| Synonyms |
Acitretin | Etretin | Isoacitretin | Isoetretin | Ro 10-1670 | Ro 101670 | Ro-10-1670 | Ro101670 | 13-cis-Acitretin | Neotigason | Soriatane | Acitretin, (Z,E,E,E)-Isomer | Ro-13-7652 | Ro137652 | Ro 13-7652 | Ro 137652 |
|
| Chemical Information |
| Molecular Formula |
C21H26O3 |
| CAS Registry Number |
55079-83-9 |
| SMILES |
CC1=CC(=C(C(=C1C=CC(=CC=CC(=CC(=O)O)C)C)C)C)OC |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
| ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
| Therapy non-responder | 08.06.01.063 | 0.001250% | | - |
|
|
|
